As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.
7 Analysts have issued a Vivoryon Therapeutics forecast:
7 Analysts have issued a Vivoryon Therapeutics forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -13 -13 |
61%
61%
|
|
| EBIT (Operating Income) EBIT | -13 -13 |
60%
60%
|
|
| Net Profit | -12 -12 |
60%
60%
|
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vivoryon Therapeutics NV is a biopharmaceutical company, which engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its product pipeline includes PQ912, PBD-C06, and PQ1565. The company was founded by Hans-Ulrich Demuth and Konrad Glund on July 25, 1997 and is headquartered in Halle, Germany.
| Head office | Netherlands |
| CEO | Frank Weber |
| Employees | 14 |
| Founded | 1997 |
| Website | www.vivoryon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


